AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Treatment Conference Digital Working experience

CAMBRIDGE, Mass.–(Company WIRE)–Jan 11, 2021–

AlloVir (Nasdaq: ALVR), a late medical-phase cell therapy company, introduced that it will current three oral presentations and one poster presentation all through the Transplantation & Cellular Therapy Conference of the American Society for Transplantation and Cellular Remedy (ASTCT) and the Middle for Worldwide Blood & Marrow Transplant Investigate (CIBMTR) having put almost February 8 – 12, 2021.

Information of the oral displays are as follows:

Presentation Title:
Financial and Scientific Burden of Virus-Associated Hemorrhagic Cystitis in Pediatric and Adult People Subsequent Allogeneic Hematopoietic Stem Cell Transplantation

Presenter: Joseph P. McGuirk, DO, The College of Kansas Cancer Middle
Assigned session: Oral Summary – Session C – Wellbeing Solutions
Session Date & Time: Monday, February 8, 2021, 2:30 p.m. CST
Presentation Tine: 2:30 – 2:45 p.m. CST
Summary Range: 19

Presentation Title:
Financial Load and Wellbeing Source Utilization Connected with dsDNA Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Presenter: Richard Maziarz, MD, Knight Most cancers Institute, Oregon Wellbeing and Science College
Assigned session: Oral Abstract – Session C – Wellbeing Expert services
Session Date & Time: Monday, February 8, 2021, 2:30 p.m. CST
Presentation Time: 3:15 – 3:30 p.m. CST
Abstract Range: 22

Presentation Title:
Allogeneic, Off-the-Shelf, Multi-Virus Particular T-Lymphocytes for the Remedy of Virus-Linked Hemorrhagic Cystitis in the Publish-HSCT Location

Presenter: Thomas Pfeiffer, MD, Center for Mobile and Gene Therapy, Baylor Faculty of Medication, Texas Children’s Hospital, Houston Methodist Healthcare facility, Houston, TX
Assigned session: Oral Summary – Session M – An infection and Immunity
Session Day & Time: Thursday, February 11, 2021, 3:00 p.m. CST
Presentation Time: 4:45 – 5:00 p.m. CST
Summary Amount: 95

Details of the poster displays are as follows:

Presentation Title: Allogeneic, Off-the-Shelf, Sars-CoV-2-Particular T Cells to Address Large-Possibility Patients with COVID-19
Presenter: Spyridoula Vasileiou, Ph.D., Middle for Cell and Gene Therapy, Baylor College or university of Medication, Texas Children’s Medical center and The Methodist Clinic
Poster range: 422

About AlloVir

AlloVir is a top late clinical-stage mobile treatment enterprise with a target on restoring organic immunity from everyday living-threatening viral diseases in individuals with weakened immune methods. The company’s impressive and proprietary technological know-how system leverages off-the-shelf, allogeneic, multi-virus unique T cells targeting devastating viruses for people with T cell deficiencies who are at chance from the life-threatening effects of viral conditions. AlloVir’s engineering and manufacturing system allows the opportunity for the procedure and prevention of a spectrum of devastating viruses with every solitary allogeneic cell therapy. The corporation is advancing a number of mid- and late-stage scientific trials across its product portfolio. For extra information check out www.allovir.com.

Forward-Hunting Statements

This push release contains ahead-wanting statements within just the that means of the Private Securities Litigation Reform Act of 1995, as amended, including, without the need of limitation, statements regarding AlloVir’s development and regulatory standing of our item candidates and its approach, organization options and emphasis. The words and phrases “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and identical expressions are intended to determine forward-seeking statements, while not all forward-seeking statements incorporate these identifying words and phrases. Any forward-seeking statements in this press release are centered on management’s recent expectations and beliefs and are topic to a range of dangers, uncertainties and crucial factors that could result in genuine events or final results to differ materially from those people expressed or implied by any forward-seeking statements contained in this push launch, like, with no limitation, these relevant to AlloVir’s financial benefits, the timing for completion of AlloVir’s medical trials of its product candidates, no matter if and when, if at all, AlloVir’s product candidates will receive approval from the U.S. Meals and Drug Administration, or Food and drug administration, or other international regulatory authorities, opposition from other biopharmaceutical firms, and other threats discovered in AlloVir’s SEC filings. AlloVir cautions you not to position undue reliance on any ahead-on the lookout statements, which converse only as of the day they are produced. AlloVir disclaims any obligation to publicly update or revise any these kinds of statements to replicate any transform in expectations or in events, disorders or conditions on which any such statements may perhaps be based mostly, or that may influence the likelihood that actual results will vary from these set forth in the ahead-on the lookout statements. Any forward-hunting statements contained in this push launch signify AlloVir’s views only as of the day hereof and should not be relied on as representing its sights as of any subsequent date.

Watch source variation on businesswire.com:https://www.businesswire.com/information/household/20210111005938/en/

Contact: Media get in touch with:

Courtney Heath

ScientPR

[email protected]

617-872-2462Investor contact:

Medha Chadha

AlloVir

[email protected]

Keyword: UNITED STATES NORTH America MASSACHUSETTS

Marketplace Key phrase: ONCOLOGY Well being INFECTIOUS Disorders HOSPITALS Clinical TRIALS PHARMACEUTICAL BIOTECHNOLOGY

Supply: AlloVir

Copyright Organization Wire 2021.

PUB: 01/11/2021 01:52 PM/DISC: 01/11/2021 01:54 PM

http://www.businesswire.com/information/property/20210111005938/en